Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2012-09-18 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2012-09-18 English
OWNERSHIP DOCUMENT
Director's Dealing
2012-09-18 English
OWNERSHIP DOCUMENT
Director's Dealing
2012-09-18 English
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a letter from NeoStem, Inc. to the SEC responding to comments on a Registration Statement on Form S-3 filed on August 24, 2012. It discusses eligibility and calculations related to the Form S-3 shelf registration. The content is a regulatory correspondence addressing SEC staff comments rather than a financial report or announcement of results. The document length is short (3276 characters) and it is a response letter, not a report or announcement of a report. It fits the category of Regulatory Filings (RNS) as it is a compliance-related communication with the SEC that does not fit other specific categories.
2012-09-18 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 on Form S-3 filed with the SEC, related to registration statements on Form S-4. It is a detailed prospectus for the offering and sale of shares of common stock underlying warrants previously issued. The content includes legal and regulatory language typical of securities registration and offering documents, focusing on capital raising and securities issuance. This type of filing is related to capital and financing activities, specifically registration and offering of securities. Therefore, the document fits best under the category Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but a full filing with detailed information about the securities offering.
2012-09-17 English
RW
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding the withdrawal of a previously filed registration statement on Form S-3/A and its immediate re-filing with the correct submission type 'POS AM'. The letter clarifies that the original filing date should be maintained and that the registration fee is offset. There is no financial data, report content, or detailed financial analysis present. The document is essentially a regulatory communication about correcting a filing type, not a financial report or announcement of financial results. Given the nature of the document as a regulatory filing correction letter, it fits best under the 'Regulatory Filings' category (RNS). The document length is short and it is a formal letter to the SEC, consistent with RNS filings.
2012-09-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.